16/08/2024 | Press release | Distributed by Public on 16/08/2024 18:00
Item 8.01 Other Events.
On August 15, 2024, Evoke Pharma, Inc. (the "Company") received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") stating that the Company has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement") and the minimum bid price matter is now closed. The letter was pursuant to a previous letter received on February 21, 2024 from Nasdaq, indicating, as previously reported, that the Company was not then in compliance with the Minimum Bid Price Requirement because its common stock had failed to maintain a minimum bid price of $1.00 or more for 30 consecutive business days.